Tetratherix Limited
AASX:TTX5.52
AUD
+0.12
(+2.22%)
ISIN
AU0000400574
Return %
Stock
S&P 500
1Y
18.71
14.20
3Y
- -
81.12
5Y
- -
68.34
Capital Structure
AUD
•
in mil. unless spec.Working Capital
AUD
•
in mil. unless spec.Growth Rates
AUD
•
in mil. unless spec.Semi-annual Revenue
AUD
•
in mil. unless spec.Semi-annual Earnings Per Share
AUD
•
in mil. unless spec.Semi-annual Dividends Per Share
AUD
•
in mil. unless spec.Company Description
- CEO
- Will Knox
- Full Time Employees
- 25
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Unit 29 Sydney NSW Australia 2015
- IPO Date
- Jun 27, 2025
- Website
- tetratherix.com
- Similar Companies
- Business
- Tetratherix Ltd (ASX:TTX) develops and commercializes advanced biomaterials for regenerative medicine through its proprietary Tetramatrix platform technology, a biostealth fluid matrix that forms injectable, implantable products with minimal foreign body reaction; core franchises include bone regeneration products such as Tegenix and TegenEOS for dental and orthopaedic applications, tissue spacing solutions like Tutelix for oncology, ophthalmic surgical access, and radiation protection, and tissue healing products including TetraDerm for reducing scar formation in surgical incisions; the platform supports modular polymer programming akin to medical Lego for targeted delivery of cells, drugs, and biologics across multiple clinical indications. Founded in 2015 and headquartered in Sydney, Australia, the company operates an ISO 13485-certified advanced manufacturing facility in Sydney with global reach targeting 10 million patients by 2035, and maintains subsidiaries such as Tetratherix BTX Ltd for international partnerships. Recent developments encompass its initial public offering and ASX listing on June 30, 2025 raising $25 million in equity plus $11 million pre-IPO from convertible notes, execution of a Master Services Agreement with Henry Schein and licensing agreement with BioOptix Inc highlighted by a stock purchase agreement on August 9, 2025, completion of three FDA pre-submissions for bone regeneration and tissue spacing franchises, pod design and equipment procurement for production scale-up, securing a $3.3 million Australian Government Industry Growth Program grant, and a new facility lease to advance manufacturing capabilities.